Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Clinical evidence

LEGEND

64 evidence topics · 10 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in HbA1c as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics, glycemic stratum, and body size in the ClinicalTrials.gov baseline table
CharacteristicLanifibranor 800 mgLanifibranor 800 mg plus empagliflozin 10 mgPlaceboTotal
Participants“12 participants”“13 participants”“14 participants”“39 participants”
Age, years, mean (SD)“55.1(11.45)”“54.2(13.48)”“54.7(13.01)”“54.6(12.38)”
Female, n“6”“8”“7”“21”
White, n“10”“10”“9”“29”
Hispanic or Latino, n“7”“4”“7”“18”
HbA1c ≥7.5%, n“8”“8”“9”“25”
Weight, kg, mean (SD)“93.30(11.614)”“103.30(12.437)”“94.50(21.269)”“97.06(16.213)”
BMI, kg/m2, mean (SD)“33.34(2.282)”“37.62(4.300)”“34.54(5.442)”“35.19(4.554)”
Median baseline characteristics in the poster
CharacteristicLanifibranorLanifibranor plus empagliflozinPlaceboTotal
Age (years)“55.5”“54.0”“55.5”“55.0”
Sex (% female)“6 (50)”“8 (62)”“7 (50)”“21 (54)”
Country (% USA)“11 (92)”“12 (92)”“12 (86)”“35 (90)”
Weight (kg)“93.9”“99.9”“97.4”“97.2”
HbA1c (%)“7.7”“8.0”“7.50”“7.7”
ALT (U/L)“53.0”“52.0”“33.0”“39.0”
HOMA-IR“9.4”“10.9”“16.3”“10.8”
cT1 (ms)“938”“926”“942”“931”
MRI-PDFF (%)“18.6”“21.1”“20.3”“19.3”
Efficacy results
Primary endpoint and HbA1c responders at the interim analysis, FAS and completers (company release, March 2024)
Interim analysis measurePlaceboLanifibranor 800 mgLanifibranor 800 mg plus empagliflozin 10 mg
HbA1c, LS mean absolute change from baseline to week 24 (%), FAS“0.26”“-1.14”“-1.59”
Participants, FAS“(n=9)”“(n=11)”“(n=10)”
HbA1c <6.5% at week 24 (%), completers“0”“55”“63”
HbA1c absolute decrease ≥1% at week 24 (%), completers“0”“64”“88”
Secondary endpoints at week 24, LS mean (95% CI), MMRM or ANCOVA (registry)
Additional liver, fibrosis, inflammatory, and metabolic biomarkers, LS means at week 24 with p values (poster)
LS mean at week 24 (p value versus placebo)LanifibranorLanifibranor plus empagliflozinPlacebo
GGT absolute change (IU/L)“-21.9 (0.010)”“-17.8 (0.015)”“22.8”
TIMP-1 absolute change (ng/mL)“-42.8 (0.040)”“-40.0 (0.056)”“-6.8”
Pro-C3 absolute change (ng/mL)“-1.26 (0.120)”“-3.54 (0.062)”“7.33”
hs-CRP relative change (%)“-32 (0.024)”“-48 (0.008)”“34”
Ferritin absolute change (µg/L)“-78 (0.002)”“-59 (0.022)”“-8”
Glucose absolute change (mmol/L)“-2.36 (0.005)”“-1.98 (0.022)”“-0.23”
Triglycerides relative change (%)“-26 (0.006)”“-27 (0.005)”“-2”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Mortality, serious adverse events, and selected other adverse events by arm (registry)
Event, affected / at risk (%)Lanifibranor 800 mgLanifibranor 800 mg plus empagliflozin 10 mgPlacebo
All-cause mortality“0/12 (0.00%)”“0/13 (0.00%)”“0/14 (0.00%)”
Other (not including serious) adverse events, total“10/12 (83.33%)”“9/13 (69.23%)”“8/14 (57.14%)”
Serious adverse event: haematuria“0/12 (0.00%)”“1/13 (7.69%)”“0/14 (0.00%)”
Anemia“2/12 (16.67%)”“0/13 (0.00%)”“1/14 (7.14%)”
Oedema peripheral“0/12 (0.00%)”“1/13 (7.69%)”“0/14 (0.00%)”
Headache“2/12 (16.67%)”“1/13 (7.69%)”“0/14 (0.00%)”
Nausea“1/12 (8.33%)”“2/13 (15.38%)”“0/14 (0.00%)”
Alopecia“2/12 (16.67%)”“0/13 (0.00%)”“0/14 (0.00%)”
Diabetes mellitus inadequate control“0/12 (0.00%)”“2/13 (15.38%)”“0/14 (0.00%)”
Blood glucose decreased“0/12 (0.00%)”“1/13 (7.69%)”“1/14 (7.14%)”
Study limitations
Summary: sample size, early stop of recruitment, open-label arm, and multiplicity
  • The protocol planned 63 participants (21 per group) for power close to 90%, assuming an HbA1c effect of 0.60% versus placebo. The protocol paused recruitment for an interim analysis once half of the planned participants were randomized; because the primary endpoint was met, recruitment was stopped. A total of 39 participants were treated (12 with lanifibranor, 13 with lanifibranor plus empagliflozin, and 14 with placebo) out of 213 screened.
  • The lanifibranor and placebo arms were double-blind, and the lanifibranor plus empagliflozin arm was open-label.
  • Treatment lasted 24 weeks, followed by a 4-week follow-up.
  • No alpha adjustment was applied for the interim analysis, the protocol describing the trial as an “exploratory proof-of-concept study”, and no multiplicity adjustment was made for secondary endpoints.
  • Inventiva does not expect to further study the combination of lanifibranor and empagliflozin.
Summary: population, endpoints, missing data, and figures that differ by source
  • MASH was diagnosed by historical histology or noninvasive methods, including cT1 thresholds on LiverMultiScan with or without MRI-PDFF. Participants had type 2 diabetes with HbA1c of 7.0% to 10.0% on diet, metformin, and/or a DPP-4 inhibitor; current or recent treatment with GLP-1 receptor agonists, insulin, or sulfonylureas was excluded. In the poster, 35 of 39 participants (90%) were enrolled in the United States.
  • The primary endpoint was the change in HbA1c; other endpoints were circulating biomarkers and MRI-based imaging.
  • In the placebo arm, 9 of 14 participants completed treatment (2 withdrawals, 2 lost to follow-up, 1 noncompliance). Two participants without post-treatment HbA1c values were excluded from the MMRM analysis, which used no explicit imputation, and 16 participants without week 24 VAT/SAT values were excluded from that ANCOVA analysis. Data after an intercurrent event (rescue medication in 2 participants and a significant diet change in 1) were excluded.
  • The interim analysis (FAS, n=11, 10, and 9) reported HbA1c changes of -1.14% and -1.59% with lanifibranor and the combination versus +0.26% with placebo; the final registry analysis reports -1.11, -1.54, and 0.16. The VAT/SAT ratio with placebo increased by 11% in the interim release and by 2% in the final poster. Completers in the combination arm are 11 in the poster and 12 in the registry participant flow.